One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.
One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.
Sold to hospitals and pharmacies through wholesalers, with prices set on the government's reimbursement list and cut in regular revisions, so the volume of generic substitution matters more than price. Profit depends on running plants efficiently as unit prices fall.
In one line: Japan's Viatris / Teva.
Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.
Headquarters: Osaka, Japan · Founded: 1929 · Employees: 3,630
Size SAWAI (4887.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.01B, the 730th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,667 on 18 Nov 2026.
Performance Over six months the shares fell 18.0%, against -9.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +7.7%); the operating margin is 8.6% (peer median 13.2%).
Valuation It trades at 12.0× forward earnings against a peer median of 20.6× (5th cheapest of 15).
Capital Return on invested capital runs 0.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥205B | ¥202B | ¥189B | ¥177B | ¥164B |
| Revenue growth | — | +7% | +7% | +8% | — |
| Gross profit | ¥58.6B | ¥58.8B | ¥56.4B | ¥54.3B | ¥50.3B |
| EBITDA | ¥34.5B | ¥36.4B | ¥35.5B | ¥36.9B | ¥33.2B |
| Net income | ¥9.52B | ¥10.4B | ¥12.0B | ¥13.7B | ¥12.7B |
| Free cash flow | -¥10.0B | -¥5.98B | ¥7.28B | ¥5.23B | -¥7.70B |
| Capital expenditure | ¥27.8B | ¥24.5B | ¥27.5B | ¥24.6B | ¥27.1B |
| Total debt | ¥126B | ¥109B | ¥95.1B | ¥87.1B | ¥77.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SAWAI 4887.T | $1.01B | -18% | +2% | 9% | 12.0× | n/a |
| Towa Pharmaceutical 4553.T | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4887.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -5.0% | 7th highest of 21 |
| 6-month return | -18.0% | -9.5% | 8th lowest of 21 |
| Distance from 52-week high | -31.9% | -30.5% | 11th highest of 21 |
| Revenue growth (TTM) | +2.4% | +7.7% | 7th lowest of 19 |
| Operating margin | 8.6% | 13.2% | 8th lowest of 19 |
| Forward P/E | 12.0× | 20.6× | 5th cheapest of 15 |
| ROIC minus cost of capital | -0.6 pp | +0.5 pp | 8th lowest of 19 |
| EV / EBITDA | 7.5× | 19.7× | 2nd cheapest of 7 |
| Net debt / EBITDA | 2.8× | 0.5× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |